Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Significant amount of institutional buying, including many new buyers, going on the past few months. This bodes very well for the future.
http://www.mffais.com/fhc
Another new high. Behaving well lately.
FHCO up .29 cents.. this stock used to be .29 years back .. see the similarities in IVOB..another womens health medical device company for fertility .34 up 5 cents on massive volume..confirms next leg up www.invobioscience.com
Nice small gain today when nearly everything else got clobbered. OBV looks great, lots of accumulation happening.
Definitely a decent quarterly earnings report. You can find a summary here:
http://finance.yahoo.com/news/The-Female-Health-Company-pz-1301675278.html?x=0&.v=1
Q3 earnings tomorrow morning.
Should be interesting. All hopes are on smooth rollout and market acceptance of F2 model.
Bought some more in the $5.70's.
Couldn't hold out for $5.50.
Fresh 52-week high.
Closed today at $6.70
Ya I haven't looked at it other than a quick glance. I'll let you know if I look at it closer (time permitting). I don't own it right now.
Hi littlefish. Good to see you stopped in. Let me know what you think of this company if you get the chance to dig deeper. I think they may have a nice little moat for five years or so. Good enough to grow the company without even trying. But if a vaccine for HIV is ever developed, you wouldn't want to be holding this stock.
Where's the DD man!?
Err, woman!?
I'll have to glance over this the next week.
nextdamnpenny, in your ref to IVOB … #board-15224
any thoughts as to why stockcharts.com won’t add em for charting?
I took an entry position in FHCO last week, got in under $6. This may go lower short term, in which case I hope to buy some more, depending on available funds.
I think the long term potential of this company is enormous. May take a few years to really take off but the potential is definitely there.
Bought some today at $5.35
I like it under $5.50. Will buy more if it goes lower.
All I know is that IA Inc has been the IR fro FHCO for over 3 years now.. FHCO has over 3,900 holders that are making big $ in a down mkt. Those fortunate enough to get in early when FHCO was a microcap otc bb co. got tons of leverage by owning it in the pennies. IVOB is at $.10 .. 1/30th the valution of FHCO with similar potnetial. According to www.ESHRE.com there are over 150,000,000 infertile couples worlwide.. yet only 300-500k get treated w/ IVF too expensive and not available in most countries. IVOB has the ww solution .. 5 patents cover the company thru 2016..
see 2 minute NECN interview with CEO, Katie Karloff (former Director of Operations of Boston Scientific..the biggest MEDICAL DEVICE Company in our lifetime) on front page of company website www.invobioscience.com
ok. you know a lot about that ir firm? i never hear of tham
Investor Awareness, Inc. is not a brokerage firm or securities dealer, so this is not a solicitation to buy or sell securities, and does not purport to be a complete analysis of Investor Awareness, Inc. clients. The material herein was provided by the clients of Investor Awareness, Inc. and is for informational purposes only. Investment in any of the Investor Awareness, Inc. clients and their respective company’s securities involves a high degree of risk and should not be considered without first reading its most recent financial statements. Investor Awareness, Inc. receives a fee from these companies for marketing services and its owners/employees may from time to time purchase, sell, or have a position in the securities of these companies.
http://www.investorawareness.com/
Tony Schor, President and Co-Founder
tony@investorawareness.com
Tony is a proven professional in corporate communications and investor relations, providing strategic communications advice to countless companies worldwide and across diverse industries for more than 18 years.
Brad Fishman, Vice President and Co-Founder
brad@investorawareness.com
Over 25 years in business, Brad has accumulated extensive business experience in diverse industries, with proven strengths in marketing, finance and communications.
Lindsay Kenoe, Account Supervisor
lindsay@investorawareness.com
Lindsay joined Investor Awareness in 2004 after receiving her B. A. in Communications from University of Iowa.
James Foy, Senior Account Manager
james@investorawareness.com
James joined Investor Awareness, Inc. in 2005 after receiving a bachelor’s degree from Illinois State University in Mass Communication.
Renae Placinski, Account Manager
renae@investorawareness.com
Renae Placinski joined in 2007 and handles all media relations efforts. She has a diverse background in media, public relations and marketing, and brings international experience and a strong business education to her current position.
Investor Awareness also employs a staff of skilled writers, account and support staff skilled in investor relations. Their efforts are critical to our ability to serve our clients well.
http://www.investorawareness.com/html/team.htm
Investor Awareness provides these primary services to our clients:
Message Crafting. Investor Awareness helps companies tell their stories in ways that enhance the interest of the financial community. We recognize the importance of demonstrating vision, and of showcasing management ability to deliver results. We craft news releases, corporate profiles, media materials and investor kits that engage the financial marketplace.
Focused Outreach. With over 10 years in business, Investor Awareness has built a powerful network of financial professionals who look to us to learn about new investment opportunities. We introduce our clients to qualified U.S. and International retail stockbrokers, investors, analysts, market makers, portfolio and fund managers through road shows, one-on-one meetings, direct telephone conversations, presentations and seminars.
Extended Outreach. To extend the reach of our clients’ messages, Investor Awareness arranges teleconference calls, web broadcasts, fax and email broadcasts, and initiates media relations campaigns in order to reach the widest possible audience.
Support and Follow Up. Creating awareness in the financial marketplace requires ongoing activity and effort. Investor Awareness excels in this area: efficient and effective follow up ensures that messages continue to reach the intended audiences.
http://www.investorawareness.com/html/services.htm
FHCO has a long way to go... have been following it for many months.. former symbol FHC on the AMEX .. it originally traded OTC BB years back. Their investor relations company is www.investorawareness.com " IA " for the last 3 years. FHCO now has 3900 shareholders. IA was recently hired to bring awareness to a very similar company IVOB that is now trading at .10 cents under $6 million valuation. www.invobioscience.com ...medical device for infertility that rivals IVF is just as effective at a fraction of the price.
IA will alert the thousands of FHCO holders to the potential of IVOB. Both Companies have med devices that are intravaginal, both got CE MARK in the EU first then pursued FDA approval, both started out as OTC BB .. FHCO mkt cap is $150mil -vs- $5mil cap for IVOB ...The upside potential for IVOB is enormous..
recent Russell 3k addition
Fresh 52-week high.
Closed today at $5.61.
Welcome to the iHub message board for Female Health Co.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
77
|
Created
|
07/07/09
|
Type
|
Free
|
Moderators |
(NASDAQ)
"FHCO"
"As of July 27,2016"
38,500,000 A/S
29,052,667 O/S
Par Value:$0.01
The Female Health Company manufactures, markets and sells the FC2 Female Condom. FC2 is the only female-controlled product approved by the U.S. Food and Drug Administration (FDA) and cleared by the World Health Organization (WHO) that provides dual protection against unintended pregnancy and sexually transmitted infections (STI’s), including HIV/AIDS. For sexually active couples, male and female condoms are the only two FDA approved and marketed products that prevent the transmission of HIV/AIDS through sexual intercourse. HIV/AIDS remains the leading cause of death worldwide amount women 15-44 years of age. More than 50% of new HIV infections are women and 80% of infections are the result of heterosexual sex.
The Company’s customers are primarily large global agencies, non-government organizations, ministries of health and other government agencies which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs. Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries world-wide. The Company’s customer base consists primarily of a small number of customers who purchase large quantities. Due to the receipt and timing of large orders, the Company experiences some quarter to quarter fluctuation in unit sales.
The Female Health Company’s headquarters are located in Chicago, Illinois. The Company has an office located in London, England and a manufacturing facility located in Selangor D.E., Malaysia.
"Zica Virus"
The recent emergence of the Zika virus creates a global health issue. The Company can make a significant contribution to preventing the spread of Zika.On February 1, 2016 WHO declared the Zika virus a global emergency. The Zika virus was first identified in 1947 in Uganda (name comes from Zika Forest in Uganda). There were no epidemic of major issues attributable to the virus for decades.
The outbreak of the virus was detected in Brazil in May 2015. Since May 2015:
| · |
| It has become epidemic in Brazil and detected in 20 additional Latin American countries. |
| · |
| It has been detected in the U.S. (Los Angeles, Texas, and Florida to date). |
| · |
| It has been detected in Spain. |
The virus is spreading and could become epidemic on a global basis.Scientists have confirmed there is a link between the virus and microencephaly, a condition that causes babies to be born with unusually small heads.There was a sharp rise in cases of microencephaly in Brazil concurrent with the Zika virus epidemic.Women who are or become pregnant and are infected may give birth to babies with microencephaly. It has also been linked to eye issues and the Guillain-Barre Syndrome, a rare neurological disorder that can result in paralysis.
The Zika virus is transmitted by mosquitoes.
In addition, Zika is transmitted through sexual intercourse.It has been reported present in both semen and urine.There has been a report the virus has also been transmitted through blood transfusions.There is the potential for a global epidemic and related births of children with microencephaly and other severe brain defects.The social and economic ramifications could be devastating.Prevention of the disease and pregnancy is critical to averting a global epidemic.Currently available prevention methods are very limited and include the following:
| · |
| Mosquito control will reduce transmission of the disease in this manner. It will not prevent pregnancy or other forms of disease transmission. |
|
|
| Female and male condoms and abstinence are the only methods that can prevent pregnancy and transmission of the virus through sex. |
The Company’s FC2 female condom can make a major contribution to the prevention of a serious disease, the birth of deformed children and the extraordinary costs that would be incurred in caring for such children.
| · |
| The Company believes it is in a better position to make this contribution than any other female condom manufacturer, as the Company has 20 years of experience and a production facility with capacity of approximately 100 million units annually. |
| · |
| The female condom is a better choice than male condoms due to the role of the women. The perception of risk among informed women of giving birth to a deformed baby is likely to be high. |
| · |
| Education is a key factor in creating risk awareness and effecting prevention. |
HOW WIDESPREAD IS THE OUTBREAK?
Active Zika outbreaks have been reported in at least 59 countries or territories, most of them in the Americas, according to the CDC. Brazil has been the country most affected.
Africa: 1 country
Cape Verde
Americas: 49 countries
Anguilla, Antigua and Barbuda, Argentina, Aruba, The Bahamas, Barbados, Belize, Bolivia, Bonaire, Brazil, British Virgin Islands, Cayman Islands, Colombia, Costa Rica, Cuba, Curaçao, Dominica, Dominican Republic, Ecuador, El Salvador, French Guiana, Grenada, Guadeloupe, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Nicaragua, Panama, Paraguay, Peru, Saba, Puerto Rico, Saint Barthelmy, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Saint Eustatius, St. Maarten, St. Kitts and Nevis, Suriname, Trinidad and Tobago, Turks and Caicos, United States, U.S. Virgin Islands, Venezuela.
Asia: 1 country
Singapore
Oceania/Pacific Islands: 8 countries
American Samoa, Fiji, Kosrae, Federated States of Micronesia, Marshall Islands, New Caledonia, Papua New Guinea, Samoa, Tonga.
"Merger"
CHICAGO – April 6, 2016 – The Female Health Company (FHC) (NASDAQ-CM: FHCO) today announced that it has entered into a definitive merger agreement with Aspen Park Pharmaceuticals, Inc. (APP), a privately held company focused on the development and commercialization of oncology and men’s and women’s health therapeutics and consumer health products. The proposed merger, subject to certain closing conditions, including approval by a two-thirds vote of FHC stockholders, is expected to close in the third quarter of 2016 and has been approved by the boards of both companies.
A special meeting of FHC shareholders is scheduled for October 31, 2016 to approve matters relating to the proposed merger.
The merged company, to be called Veru Healthcare Inc.
Aspen Park Pharmaceuticals, Inc. is a privately held therapeutics company focused on the development and commercialization of pharmaceutical and consumer health products for men’s and women’s health and oncology. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, gout, sexual dysfunction, and prostate cancer. For women, product candidates are for advanced breast and ovarian cancers and for female sexual health. Aspen Park Pharmaceuticals is planning to launch in the United States the PREBOOST™ OTC product for treating premature ejaculation in Q4 of fiscal 2016. Aspen Park Pharmaceuticals has offices in New York City, New York. For more information on PREBOOST™ OTC product visit http://preboost.com/ or for more information on APP visit http://aspenparkpharma.com/.
"Website"
http://femalehealth.com/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |